Intabio, Inc. and Protein Metrics Inc., developers of advanced analytical tools for accelerating biopharmaceutical development and manufacturing, today announced a co-development and co-marketing agreement to couple Intabio’s Blaze™ instrument system with the Byos® software suite from Protein Metrics. The integrated Blaze-Byos platform will address a critical bottleneck for biopharmaceutical developers by automating analysis of large protein structure/quality data sets to confirm product consistency and quality.
With Intabio’s Blaze system, drug developers can monitor multiple Critical Quality Attributes (CQAs) directly on intact biotherapeutic proteins. The system couples two gold-standard analytical techniques – imaged capillary isoelectric focusing (iCIEF) and high-resolution mass spectrometry (HRMS) – into a single 15-minute assay with a hundred times the throughput of legacy approaches.
Protein Metrics’ Byos Platform allows researchers to move from raw data files to report in just minutes, with the click of a mouse. Designed to support users with a range of expertise Protein Metrics software is installed in over 100 biopharmaceutical companies worldwide. By launching best-in-class protein analysis workflows, Byos significantly improves laboratory efficiency, reproducibility, and reporting across the development pipeline.
“The Blaze system eliminates a serious bottleneck created by traditional, cumbersome laboratory approaches to identifying and characterizing CQAs, while the Byos platform dramatically boosts the speed of MS data analysis,” said Intabio’s CEO and co-founder, Lena Wu, Ph.D. “The Blaze-Byos combination will enable critical drug development decisions to be made months earlier.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“For organizations that traditionally rely on cIEF measurements, the combination of Byos workflows with the Blaze platform offers a rapid, vendor-neutral means to provide detailed mass spec analysis of sample heterogeneity and comparability,” said Eric Carlson, President & CEO of Protein Metrics.
Source: BioSpace